Biofrontera AG (ETR:B8FK)

Market Cap	14.83M +1.9%
Revenue (ttm)	23.26M +7.3%
Net Income	-2.14M
EPS	-0.36
Shares Out	6.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,271
Average Volume	1,525
Open	2.460
Previous Close	2.430
Day's Range	2.400 - 2.480
52-Week Range	2.160 - 2.960
Beta	-0.26
RSI	45.57
Earnings Date	Mar 31, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 76
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: B8FK

Financial Performance

In 2024, Biofrontera AG's revenue was 21.67 million, a decrease of -32.81% compared to the previous year's 32.25 million. Losses were -4.35 million, 1078.9% more than in 2023.